Bristol Myers Squibb partnered with Anthropic to deploy Claude AI across global operations, aiming to embed AI into day-to-day workflows rather than rely solely on chat interfaces. The effort targets engineering acceleration via Claude Code and operational support for drug development tasks such as trial documentation and regulatory submission support. The collaboration frames Claude as a shared intelligence layer for more than 30,000 BMS employees spanning research, clinical development, manufacturing, and commercial functions. BMS expects near-term impact by integrating Claude into priority processes where AI reasoning can extract signal from decades of scientific and clinical data silos. Separately, Incyte expanded its AI partnerships with Genesis Molecular AI and Edison, signaling continued build-out of machine-learning capabilities across portfolio decision-making. Together, the moves show major biopharma players translating AI from pilots into system-level deployment plans.